Drug Profile
Etanercept biosimilar - Dong-A ST/Meiji Seika Pharma
Alternative Names: DA-3853; DMB-3853Latest Information Update: 17 Nov 2021
Price :
$50
*
At a glance
- Originator Dong-A Pharmaceutical; Meiji Seika Pharma
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins; Skin disorder therapies
- Mechanism of Action Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Rheumatoid arthritis
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 28 Jan 2018 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in USA (Parenteral)
- 19 Jun 2015 Etanercept biosimilar - Dong-A ST/Meiji Seika Pharma is available for licensing in World (excluding South Korea and Japan) as of 19 Jun 2015 (Dong A ST Annual Report 2014 Pipeline)